INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). See more

home_hero_image

GIVE YOUR ESA RELAPSED/REFRACTORY RS-, RS+, OR ESA-INELIGIBLE
LR-MDS PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA

THE POSSIBILITY OF
ZERO TRANSFUSIONS1

In the IMerge phase 3, double-blind, placebo-controlled clinical trial, 39.8% (n=47/118) (95% CI, 30.9, 49.3) of patients who received RYTELO achieved red blood cell transfusion independence for ≥8 consecutive weeks vs 15% (n=9/60) with placebo (95% CI, 7.1, 26.6) (P<0.001)1

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for Management of Lower-Risk MDS Disease, Treatment of Symptomatic Anemia, were updated to include imetelstat (RYTELOTM) as an NCCN Category 1* and Category 2A† treatment option for certain patients.2

*Category 1: Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.2

†Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.2

Icon of a forward arrow with three dots.
Continuous RBC-TI benefit1,3
  • Primary Endpoint: 39.8% achieved RBC-TI ≥8 consecutive weeks with RYTELO (95% CI, 30.9, 49.3) vs 15% with placebo (95% CI, 7.1, 26.6) (P<0.001)
Learn more about RBC-TI benefit
Icon of a graph trend
Durability of response3
  • Secondary Endpoint: RYTELO ≥8-week RBC-TI responders achieved mDoR of 51.6-week RBC-TI (95% CI, 26.9, 83.9) vs 13.3-week RBC-TI with placebo (95% CI, 8.0, 24.9) (HR, 0.2; 95% CI, 0.1, 0.6; P<0.001)‡
Learn more about durability of response
Icon of a person and a shield.
Well-characterized safety profile1
  • Treatment was discontinued due to adverse reactions in 15% (n=17) of patients receiving RYTELO1
    • 7.6% (n=9) of RYTELO patients discontinued due to cytopenias vs 0% on placebo4
  • Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%), fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%)1
  • Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache1
Learn more about the RYTELO safety profile

‡Not all patients treated with RYTELO experienced 51.6 weeks of continuous RBC-TI.3

Icon of the telomerase enzyme.
Telomerase in LR-MDS
Icon of a vial with a calculator.
Dosing
Icon of a phone with a check mark.
Register for Updates
Icon of a person with speech bubble.
Request a Rep

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESA, erythropoiesis-stimulating agent; HR, hazard ratio; LR-MDS, lower-risk myelodysplastic syndromes; mDoR, median duration of response; RBC-TI, red blood cell transfusion independence; RS, ring sideroblasts.

References: 1. RYTELO. Prescribing information. Geron Corp.; 2024. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed July 31, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10423):249-260. 4. Data on file. Geron Corporation. Foster City, CA.

INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombocytopenia

RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.

Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Neutropenia

RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.

Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Infusion-Related Reactions

RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.

Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.

Embryo-Fetal Toxicity

RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%), fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).

Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.

Please see full Prescribing Information, including Medication Guide.

You are encouraged to report adverse events related to Geron products by calling 1-855-437-6664 (1-855-GERON-MI) (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.